Join the Neuromyelitis Optica group to help and get support from people like you.
Neuromyelitis Optica News
Related terms: NMOSD
Ultomiris Approved in the US for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)
25 March 2024 – Ultomiris (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with...
FDA Approves Enspryng (satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder
South San Francisco, CA – August 14, 2020 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng (satralizumab-mwge) as the...
FDA Approves Uplizna (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) – Viela Bio (Nasdaq:VIE) today announced that the U.S. Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) for the treatment...
Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder
BOSTON--(BUSINESS WIRE)--June 27, 2019 – Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Soliris (eculizumab) for the treatment of...
Ask a question
To post your own question to this support group, sign in or create an account.